\u003cp\u003eA brand-new title in the field of dermatology, \u003cb\u003e\u003ci\u003eTherapy for Severe Psoriasis\u003c/i\u003e \u003c/b\u003eprovides the ultimate coverage of the treatment options available for today's most serious cases, including biologics and oral therapies. \u003cb\u003eIt features discussions of the newest drug therapies\u003c/b\u003e, recent FDA-approved biosimilars, and combination approaches to care, while an \u003cb\u003eoverview chapter\u003c/b\u003e was designed to aid those new to the field in understanding the nuances of difficult-to-treat subtypes of psoriasis. Comprehensive and focused,\u003cb\u003e\u003ci\u003e Therapy for Severe Psoriasis \u003c/b\u003e\u003c/i\u003ewill be a welcome addition to the library of \u003cb\u003eany dermatologist seeking in-depth information\u003c/b\u003e on the challenges of this condition.\u003c/p\u003e\u003cul\u003e \u003cli\u003eEach of the 16 chapters includes either an \u003cb\u003ein-depth focus on a single therapy\u003c/b\u003e or an \u003cb\u003eoverview of a unique aspect of psoriasis\u003c/b\u003e, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab.\u003c/li\u003e \u003cli\u003eTakes an evidence-based approach to \u003cb\u003ehard-to-treat severe psoriasis\u003c/b\u003e.\u003c/li\u003e \u003cli\u003eDiscusses the \u003cb\u003enewest drug therapies\u003c/b\u003e (such as ixekizumab), plus \u003cb\u003erecent FDA-approved biosimilars\u003c/b\u003e, a topic unique to this particular psoriasis text.\u003c/li\u003e \u003cli\u003e\u003cb\u003ePresents combination approaches\u003c/b\u003e for instances when standard treatments are not successful.\u003c/li\u003e \u003cli\u003e\u003cb\u003eIncludes an overview chapter\u003c/b\u003e to help beginners understand the nuances of the disorder.\u003c/li\u003e\u003c/ul\u003e
nl
en